CVS has had trouble adapting to the changing healthcare landscape and admits it has struggled to increase profits and stock performance.
To combat its recent financial problems, the company decided to replace its CEO, Karen Lynch. CVS veteran and EVP David Joyner was chosen as her immediate replacement. Despite the change, the company has not dramatically affected its stock value. Today, prices have stabilized and continue to rise after plummeting Friday.
Following the announcement, Karen Lynch took to X to tell her employees, “I am confident that CVS Health will continue to thrive and lead the way in healthcare. The talent, passion, and resilience within this organization are unparalleled, and I have no doubt that you will continue to drive positive change for the people and communities that depend on you.”
With Lynch’s departure, only 45 female CEOs remain in the S&P 500.
CVS warned investors that its coming earnings will likely again fall short of Wall Street expectations. However, the new leadership change is hoped to keep the company afloat.
In a press release earlier this year, CVS said, “In light of continued elevated medical cost pressures in the Health Care Benefits segment, investors should no longer rely on the Company’s previous guidance provided on its second quarter 2024 earnings call on August 7, 2024”.
The company is set to report third-quarter earnings on Nov. 6.
By CEO NA Editorial Staff
